Study Links Sleep Duration and Quality to Alzheimer Disease Biomarkers

Previous studies have shown that poor sleep quality and delayed entry into rapid eye movement (REM) sleep may increase the risk of developing dementia. Two large longitudinal studies revealed that older adults who slept less than five hours a night were twice as likely to develop dementia and die within five years compared to those who slept between six to eight hours. These findings remained significant after factoring in demographic and health variables.

In a study involving over 2,800 U.S. adults aged 65 and older, similar patterns were observed. Additionally, a European study of nearly 8,000 participants linked consistently sleeping six hours or less at ages 50, 60, and 70 to a 30% increased risk of dementia relative to those sleeping seven hours. This association persisted after controlling for various health and social factors and was corroborated by objective sleep measurements.

Further research published in Alzheimer’s & Dementia suggested that taking longer to reach REM sleep might indicate early signs of Alzheimer disease, correlating with higher amyloid and tau levels as well as reduced brain-derived neurotrophic factor. Participants who entered REM sleep after more than 193 minutes showed significantly elevated amyloid-β and phosphorylated tau levels, even after adjusting for demographic and health factors. However, total sleep time and sleep efficiency did not appear to correlate with dementia biomarkers.

The findings underscore the significance of disrupted sleep architecture, particularly in terms of delayed or diminished REM and slow-wave sleep, which may hinder memory consolidation and contribute to neurodegeneration. This highlights the potential of REM sleep as an early indicator and modifiable factor in dementia risk, although further intervention trials are necessary to confirm if improving REM sleep can influence disease progression.

The review specifically examined fluid biomarkers of Alzheimer pathology and neurodegeneration, including cerebrospinal fluid and blood biomarkers: Aβ, p-tau181, t-tau, neurofilament light chain level (NfL), and glial fibrillary acidic protein (GFAP). Investigators sifted through publications from various databases up to September 2024, with 20 studies meeting the criteria.

While many studies did not report significant associations, trends indicated that shorter sleep was related to higher levels of cerebrospinal fluid t-tau and p-tau181, as well as lower Aβ42 levels. Longer sleep durations yielded variable associations, some indicating worse and others better biomarker profiles. Notably, two studies found U-shaped relationships, suggesting that both short (≤5-6 hours) and long (≥8 hours) sleep durations are associated with altered biomarker profiles. However, the predominance of cross-sectional studies and the diversity of findings limit the ability to draw firm conclusions about the relationship between sleep duration and biomarkers. The authors advocate for further exploration into emerging blood-based biomarkers and the temporal dynamics between sleep patterns and changes in Alzheimer disease biomarkers.